KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Deferred Taxes (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Deferred Taxes for 16 consecutive years, with -$202.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Deferred Taxes rose 89.54% year-over-year to -$202.0 million, compared with a TTM value of -$1.2 billion through Dec 2024, up 7.0%, and an annual FY2025 reading of -$639.0 million, up 47.15% over the prior year.
  • Deferred Taxes was -$202.0 million for Q4 2024 at Thermo Fisher Scientific, up from -$400.0 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $339.0 million in Q2 2022 and bottomed at -$1.9 billion in Q4 2023.
  • Average Deferred Taxes over 5 years is -$15.8 million, with a median of $163.0 million recorded in 2020.
  • The sharpest move saw Deferred Taxes surged 1512.5% in 2022, then plummeted 1551.88% in 2023.
  • Year by year, Deferred Taxes stood at $56.0 million in 2020, then soared by 242.86% to $192.0 million in 2021, then crashed by 30.73% to $133.0 million in 2022, then tumbled by 1551.88% to -$1.9 billion in 2023, then surged by 89.54% to -$202.0 million in 2024.
  • Business Quant data shows Deferred Taxes for TMO at -$202.0 million in Q4 2024, -$400.0 million in Q3 2024, and -$860.0 million in Q2 2024.